This Fool considers how two low-risk and well-established FTSE shares could offer stability and growth during a period of ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.

I’m yet to invest in the stock as I already hold shares in Reckitt and GSK. However, I think it’s a good long-term investment to consider and one I’ll be keeping an eye on this year.

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Teva Pharmaceutical Industries Ltd. ADR 0.46% $24.53B ...

At close: January 23 at 4:00:02 PM EST ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...